Kayla Ponder to Promoter Regions, Genetic
This is a "connection" page, showing publications Kayla Ponder has written about Promoter Regions, Genetic.
Connection Strength
0.515
-
Therapeutic levels of functional human factor X in rats after retroviral-mediated hepatic gene therapy. Blood. 1997 Feb 15; 89(4):1254-9.
Score: 0.099
-
Retroviral vector sequences may interact with some internal promoters and influence expression. Hum Gene Ther. 1996 Jan 20; 7(2):159-71.
Score: 0.092
-
Quantitative evaluation of liver-specific promoters from retroviral vectors after in vivo transduction of hepatocytes. Blood. 1994 Nov 15; 84(10):3394-404.
Score: 0.085
-
Liver-directed gene therapy: quantitative evaluation of promoter elements by using in vivo retroviral transduction. Proc Natl Acad Sci U S A. 1994 Feb 15; 91(4):1460-4.
Score: 0.081
-
Evaluation of relative promoter strength in primary hepatocytes using optimized lipofection. Hum Gene Ther. 1991; 2(1):41-52.
Score: 0.065
-
Therapeutic levels of human protein C in rats after retroviral vector-mediated hepatic gene therapy. J Clin Invest. 1998 Jun 15; 101(12):2831-41.
Score: 0.027
-
Liver-directed gene therapy: a retroviral vector with a complete LTR and the ApoE enhancer-alpha 1-antitrypsin promoter dramatically increases expression of human alpha 1-antitrypsin in vivo. Hum Gene Ther. 1996 Mar 20; 7(5):637-45.
Score: 0.023
-
Liver-directed gene therapy: evaluation of liver specific promoter elements. J Surg Res. 1994 Jun; 56(6):510-7.
Score: 0.021
-
Mouse hepatocytes migrate to liver parenchyma and function indefinitely after intrasplenic transplantation. Proc Natl Acad Sci U S A. 1991 Feb 15; 88(4):1217-21.
Score: 0.016
-
Optimization of liver-directed retroviral gene delivery. Transplant Proc. 1994 Dec; 26(6):3379-80.
Score: 0.005